GSK (NYSE: GSK) continues share buyback, adding to treasury stock

Rhea-AI Filing Summary

GSK plc reports further repurchases of its ordinary shares between 1 and 5 June 2026 as part of its existing buyback programme, executed through Citigroup Global Markets Limited. Daily buybacks ranged from 217,096 to 496,356 shares, with volume-weighted average prices between 1,824.85 GBp and 1,922.23 GBp per share.

Since 11 May 2026 the company has purchased 6,233,812 ordinary shares. After the latest transactions, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue, giving the same number of total voting rights. Treasury shares represent 6.61% of voting rights, a figure shareholders can use when assessing disclosure thresholds.

Key Figures

Shares bought 1 June 2026: 496,356 shares VWAP 1 June 2026: 1,855.38 GBp/share Shares bought 5 June 2026: 217,096 shares +5 more

8 metrics

Shares bought 1 June 2026 496,356 shares Aggregate number of ordinary shares purchased on 1 June 2026

VWAP 1 June 2026 1,855.38 GBp/share Volume weighted average price paid per share on 1 June 2026

Shares bought 5 June 2026 217,096 shares Aggregate number of ordinary shares purchased on 5 June 2026

VWAP 5 June 2026 1,922.23 GBp/share Volume weighted average price paid per share on 5 June 2026

Shares bought since 11 May 2026 6,233,812 shares Total ordinary shares purchased under the programme since 11 May 2026

Treasury share balance 267,612,098 shares Ordinary shares held in treasury following the reported purchases

Shares in issue 4,048,628,915 shares Ordinary shares in issue excluding treasury shares after purchases

Treasury voting rights percentage 6.61% Percentage of voting rights attributable to treasury shares under DTR 5.5.1R

Key Terms

Treasury shares, buyback programme, voting rights, DTR 5.5.1R, +1 more

5 terms

Treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

buyback programme financial

"Such share purchases form part of the Company's existing buyback programme"

voting rights financial

"the total number of voting rights in the Company will be 4,048,628,915"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

DTR 5.5.1R regulatory

"The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases"

Market Abuse Regulation (EU) No 596/2014 regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
1 June 2026	496,356	1,832.50	1,882.00	1,855.38
2 June 2026	337,370	1,805.00	1,841.00	1,824.85
3 June 2026	367,570	1,814.50	1,856.50	1,836.87
4 June 2026	225,000	1,863.50	1,904.00	1,884.74
5 June 2026	217,096	1,908.00	1,939.00	1,922.23

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 6,233,812 ordinary shares.

Following the above purchases, the Company will hold 267,612,098 ordinary shares in treasury and have 4,048,628,915 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,048,628,915. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.61 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4193H_1-2026-6-8.pdf

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 08, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) announce in this June 2026 Form 6-K?

GSK reported purchasing additional ordinary shares between 1 and 5 June 2026 under its existing buyback programme. The shares were acquired via Citigroup Global Markets and will be held as treasury shares, reducing freely tradable stock while maintaining overall voting rights.

How many GSK shares have been repurchased since 11 May 2026?

Since 11 May 2026, GSK has repurchased 6,233,812 ordinary shares. These buybacks are part of an existing programme and the shares are being held in treasury, which can influence share supply and per-share metrics over time.

What is GSK’s current treasury share position and voting rights?

Following the latest purchases, GSK holds 267,612,098 ordinary shares in treasury and has 4,048,628,915 ordinary shares in issue. The total number of voting rights is also 4,048,628,915, providing a key reference point for regulatory ownership disclosures.

What percentage of GSK’s voting rights are held in treasury shares?

GSK states that 6.61% of its voting rights are attributable to ordinary shares held in treasury. This percentage helps investors judge how much of the company’s equity is not currently in public circulation but still part of the overall capital structure.

At what prices did GSK buy back shares in early June 2026?

Between 1 and 5 June 2026, GSK’s volume-weighted average purchase prices ranged from 1,824.85 GBp to 1,922.23 GBp per share. Each trading day included a disclosed lowest and highest price within that range on the London market venues used.

How were GSK’s share repurchases executed in this period?

The repurchases were carried out by Citigroup Global Markets Limited under a non-discretionary agreement dated 8 May 2026. Trades occurred on the London Stock Exchange and CBOE Europe order books, with full transaction details available via a linked schedule document.